These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 12578514

  • 1. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L.
    Arch Intern Med; 2003 Feb 10; 163(3):333-9. PubMed ID: 12578514
    [Abstract] [Full Text] [Related]

  • 2. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
    Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jönsson B.
    Can J Cardiol; 2009 Nov 10; 25(11):e362-9. PubMed ID: 19898698
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA, Coupal L, Paquet S, Zowall H.
    Arch Intern Med; 1999 Mar 22; 159(6):593-600. PubMed ID: 10090116
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL, Lyseng-Williamson KA.
    Pharmacoeconomics; 2007 Mar 22; 25(12):1031-53. PubMed ID: 18047388
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Mar 22; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 8. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT.
    Value Health; 2011 Mar 22; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [Abstract] [Full Text] [Related]

  • 9. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.
    Pharmacoeconomics; 2008 Mar 22; 26(4):329-39. PubMed ID: 18370567
    [Abstract] [Full Text] [Related]

  • 10. [Atorvastatin in primary prevention].
    Kültürsay H.
    Turk Kardiyol Dern Ars; 2009 Mar 22; 37 Suppl 2():17-22. PubMed ID: 19404046
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C.
    J Med Econ; 2012 Mar 22; 15 Suppl 1():45-54. PubMed ID: 22954062
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA, Duncan BB, Ziegelmann PK, Stella SF, Vieira JL, Restelatto LM, Polanczyk CA.
    Arq Bras Cardiol; 2015 Jan 22; 104(1):32-44. PubMed ID: 25409878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
    Grover S, Coupal L, Lowensteyn I.
    Can J Cardiol; 2008 Dec 22; 24(12):891-8. PubMed ID: 19052668
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.